✦ LIBER ✦

Phase ii trial of D-Trp-6-LH-RH in advanced breast cancer

✍ Scribed by G. Mathe; R. Helling; J. Gastlaburu; M.L.. VoVan; G. Prévot; P. Ribaud; C. Jasmin; F. Lévi; M. Musset; J.L. Misset

Book ID: 116006721
Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 155 KB
Volume: 28
Category: Article
ISSN: 0022-4731
DOI: 10.1016/0022-4731(87)91392-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of D-Trp-6-LH-RH (long re

Phase II trial of D-Trp-6-LH-RH (long releasing formulation) in advanced prostatic cancer

✍ G. Mathé; R. Keiling; J. Gastlaburu; M.L. VoVan; G. Prévot; J.M. Vannetzel; R. D 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Treatment of advanced prostatic carcinom

Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH

✍ D. Gonzalez-Barcena; P.L. Perez; S. Ureta; H. Berea; A. Graef; M. Becerril; A.M. 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 104 KB

An oriented phase-II trial ofd-Trp6-LH-R

An oriented phase-II trial ofd-Trp6-LH-RH in patients with prostatic carcinoma

✍ G. Mathé; M. L. Vovan; J. Duchier; J. L. Misset; P. Morin; R. Keiling; L. Schwar 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 246 KB

Phase-II trial of tamoxifen in advanced

Phase-II trial of tamoxifen in advanced breast cancer

✍ R. G. Wiggans; P. V. Woolley; Tarilyn Smythe; D. Hoth; J. S. Macdonald; Linda Gr 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 338 KB

An LH-RH antagonist inhibits the behavio

An LH-RH antagonist inhibits the behavioral effects of the agonist D-TRP-6-LH-RH in mice

✍ Tibor Kádár; Gyula Telegdy; Andrew V. Schally 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 407 KB

Recombinant gamma interferon in advanced

Recombinant gamma interferon in advanced breast cancer: A phase II trial

✍ Hyman B. Muss; Mary Caponera; Patricia J. Zekan; Don V. Jackson; John J. Stuart; 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 365 KB

Fifteen patients with advanced carcinoma of the breast who had failed prior chemotherapy, were treated with recombinant gamma interferon at a dose of 2mg/m2 (1mg = 2.4 X 10(7) international units) intravenously for five consecutive days every other week. The median patient age was 51 and all patient